Literature DB >> 2320569

Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors.

M S Dennis1, W J Henzel, R M Pitti, M T Lipari, M A Napier, T A Deisher, S Bunting, R A Lazarus.   

Abstract

The purification, complete amino acid sequence, and biological activity are described for several homologous snake venom proteins that are platelet glycoprotein (GP) IIb-IIIa antagonists and potent inhibitors of platelet aggregation. The primary structures of kistrin (from Agkistrodon rhodostoma), bitan (from Bitis arietans), three isoforms of trigramin (from Trimeresusus gramineus), and an isoform of echistatin (from Echis carinatus) were determined by automated sequence analysis and fast atom bombardment mass spectrometry analysis. Each of the protein in this family, which range from 47 to 83 residues, contains an Arg-Gly-Asp amino acid sequence found in protein ligands that binds to GPIIb-IIIa, a high (17 +/- 1%) cysteine content conserved in the primary sequence, and a homologous N-terminal region absent only in the echistatin isoforms. Each protein directly inhibits the interaction of purified platelet GPIIb-IIIa to immobilized fibrinogen about 100 times more effectively than does the pentapeptide Gly-Arg-Gly-Asp-Ser; IC50 values range from 1.1 to 3.0 nM. The IC50 value for the inhibition of platelet aggregation, using human platelet-rich plasma stimulated with ADP, ranges from 110 to 550 nM for the various proteins, about 1000-fold more potent than Gly-Arg-Gly-Asp-Ser. Kistrin binds reversibly to both resting and ADP-activated human platelets with high affinity (Kd = 10.8 nM and 1.7 nM, respectively) and to purified GPIIb-IIIa with a lower affinity (Kd = approximately 100 nM). Finally, kistrin injected at 1.0 mg/kg into rabbits reversibly inhibits platelet aggregation ex vivo over 30 min without induction of thrombocytopenia. We propose that these proteins are members of a general class of proteins found in the venom of pit vipers that inhibit platelet aggregation by antagonism of the GPIIb-IIIa-fibrinogen interaction and as such serve as potential antithrombotic agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320569      PMCID: PMC53711          DOI: 10.1073/pnas.87.7.2471

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Expression of recombinant platelet glycoprotein IIbIIIa results in a functional fibrinogen-binding complex.

Authors:  S C Bodary; M A Napier; J W McLean
Journal:  J Biol Chem       Date:  1989-11-15       Impact factor: 5.157

Review 2.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

3.  Characterization of a potent platelet aggregation inhibitor from Agkistrodon rhodostoma snake venom.

Authors:  T F Huang; Y J Wu; C Ouyang
Journal:  Biochim Biophys Acta       Date:  1987-09-11

4.  Human platelets possess an inducible and saturable receptor specific for fibrinogen.

Authors:  G A Marguerie; E F Plow; T S Edgington
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

5.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

6.  Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen.

Authors:  R L Nachman; L L Leung
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

Review 7.  The influence of snake venom enzymes on blood coagulation.

Authors:  F Kornalík
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

8.  Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation.

Authors:  G A Marguerie; T S Edgington; E F Plow
Journal:  J Biol Chem       Date:  1980-01-10       Impact factor: 5.157

9.  Exposure of platelet fibrinogen receptors by ADP and epinephrine.

Authors:  J S Bennett; G Vilaire
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

10.  Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components.

Authors:  I Lipinska; B Lipinski; V Gurewich
Journal:  J Lab Clin Med       Date:  1974-10
View more
  46 in total

1.  Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins.

Authors:  B Wattam; D Shang; S Rahman; S Egglezou; M Scully; V Kakkar; X Lu
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

2.  Three-dimensional model of the human platelet integrin alpha IIbbeta 3 based on electron cryomicroscopy and x-ray crystallography.

Authors:  Brian D Adair; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-18       Impact factor: 11.205

3.  Viper snakebite causing symptomatic intracerebral haemorrhage.

Authors:  Deborah Bartholdi; Claudia Selic; Jürg Meier; Hans H Jung
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 4.  The human platelet fibrinogen receptor: clinical and therapeutic significance.

Authors:  M Cahill; R Mistry; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

5.  Effects of limiting extension at the alphaIIb genu on ligand binding to integrin alphaIIbbeta3.

Authors:  Robert Blue; Jihong Li; Jonathan Steinberger; Marta Murcia; Marta Filizola; Barry S Coller
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

6.  Integrins contribute to initial morphological development and process outgrowth in rat adult hippocampal progenitor cells.

Authors:  Matthew M Harper; Eun-Ah Ye; Christopher C Blong; Mark L Jacobson; Donald S Sakaguchi
Journal:  J Mol Neurosci       Date:  2009-06-05       Impact factor: 3.444

7.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

8.  Laboratory reptile surgery: principles and techniques.

Authors:  Leanne C Alworth; Sonia M Hernandez; Stephen J Divers
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-01       Impact factor: 1.232

9.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Drug Dev Res       Date:  2008       Impact factor: 4.360

10.  LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Authors:  Shizhen Zhu; Xiaoling Zhang; Nina Weichert-Leahey; Zhiwei Dong; Cheng Zhang; Gonzalo Lopez; Ting Tao; Shuning He; Andrew C Wood; Derek Oldridge; Choong Yong Ung; Janine H van Ree; Amish Khan; Brittany M Salazar; Edroaldo Lummertz da Rocha; Mark W Zimmerman; Feng Guo; Hong Cao; Xiaonan Hou; S John Weroha; Antonio R Perez-Atayde; Donna S Neuberg; Alexander Meves; Mark A McNiven; Jan M van Deursen; Hu Li; John M Maris; A Thomas Look
Journal:  Cancer Cell       Date:  2017-08-31       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.